Attgeno AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.attgeno.com
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
Phase 2
Recruiting
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Attgeno AB
- Target Recruit Count
- 12
- Registration Number
- NCT05699486
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Anaesthesiology and Intensive Care, Gothenburg, Sweden
🇸🇪Örebro University Hospital, Vascular and Thoracic Department (Kärl-Thoraxkliniken), Örebro, Sweden
A First-in-Human Study to Assess the Safety and Tolerability of PDNO
Phase 1
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Attgeno AB
- Target Recruit Count
- 38
- Registration Number
- NCT04891354
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension
Phase 1
Withdrawn
- Conditions
- Pulmonary HypertensionCOVID-19
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Attgeno AB
- Registration Number
- NCT04885491
- Locations
- 🇸🇪
Örebro University Hospital, Örebro, Sweden
🇸🇪Danderyd Hospital, Danderyd, Sweden
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
Completed
- Conditions
- COVIDHypertension, PulmonaryRight Ventricular Overload
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Attgeno AB
- Target Recruit Count
- 67
- Registration Number
- NCT04459364
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
© Copyright 2025. All Rights Reserved by MedPath